Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ETX-018810 · 2 trials · 3 indications
Change from baseline in the weekly average of the daily pain score as derived from the subject's responses on the Pain Intensity Numerical Rating Scale (PI-NRS), a 10 point scale from 0 being the least (No Pain) to 10 being the most (Worst Possible Pain).
| Arm | Type | Description |
|---|---|---|
| ETX-018810 | EXPERIMENTAL | Drug: ETX-018810 BID for 4 weeks |
| Placebo | PLACEBO_COMPARATOR | Matching Placebo BID for 4 weeks |
| Name | Type | Description |
|---|---|---|
| ETX-018810 | DRUG | Study Drug |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * The subject has pain consistent with a diagnosis of chronic lumbosacral radiculopathy due to injury of the lumbosacral nerve root(s) * The subject reports at least moderate pain intensity at screening. * The subject's onset of leg pain due to LSRP is at least 3 months * The su...
ETX-018810 is an investigational small molecule being developed for the treatment of diabetic peripheral neuropathic pain and lumbosacral radiculopathy. It is in Phase 2 clinical development and is not yet approved by the FDA.
ETX-018810 is being developed by Climb Bio, Inc., a biopharmaceutical company traded on the stock exchange under the ticker CLYM.
ETX-018810 is in Phase 2 clinical development. Two Phase 2 trials have been completed, one in diabetic peripheral neuropathic pain and one in lumbosacral radiculopathy. The drug remains investigational and has not been approved.
ETX-018810 has been studied in two completed Phase 2 trials. NCT04688671 evaluated the drug in 167 patients with diabetic peripheral neuropathic pain, and NCT04778592 evaluated it in 149 subjects with lumbosacral radicular pain. Both trials were conducted in the United States.
ETX-018810 is the drug name used in clinical trials for this investigational small molecule. No other names for this drug have been reported.